Answers are grounded in this paper and cite their sources.
This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient perspective in Japan.
No takes yet. Share an insight, caveat, or question.
Yanagi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: